| 9.125 -0.405 (-4.25%) | 04-28 11:17 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.17 |
1-year : | 12.3 |
| Resists | First : | 9.56 |
Second : | 10.53 |
| Pivot price | 9.75  |
|||
| Supports | First : | 8 |
Second : | 6.65 |
| MAs | MA(5) : | 9.79 |
MA(20) : | 9.53 |
| MA(100) : | 7.46 |
MA(250) : | 4.55 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 53.7 |
D(3) : | 67.8 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 11.6 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMMX ] has closed above bottom band by 18.8%. Bollinger Bands are 35.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.55 - 10.63 | 10.63 - 10.69 |
| Low: | 9.34 - 9.42 | 9.42 - 9.48 |
| Close: | 9.42 - 9.55 | 9.55 - 9.64 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Mon, 27 Apr 2026
Immix Biopharma (IMMX) price target increased by 11.73% to 18.62 - MSN
Thu, 16 Apr 2026
Immix Biopharma (NASDAQ:IMMX) Trading Down 4.6% - Time to Sell? - MarketBeat
Thu, 09 Apr 2026
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Thu, 09 Apr 2026
Immix Biopharma lines up investor meetings at Jefferies event - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 22 (%) |
| Held by Institutions | 48.3 (%) |
| Shares Short | 3,120 (K) |
| Shares Short P.Month | 2,970 (K) |
| EPS | -0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.3 % |
| Return on Equity (ttm) | -55 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -10.39 |
| PEG Ratio | 0 |
| Price to Book value | 5.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|